Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
August 10, 2023 08:08 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Executive Leadership Changes
August 02, 2023 16:11 ET
|
Molecular Templates, Inc.
Dr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley to assume the role of Chief Operating...
Molecular Templates Announces Up to $40 Million Private Placement Offering
July 13, 2023 08:14 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Debt Payoff and Restructuring
June 16, 2023 20:56 ET
|
Molecular Templates, Inc.
Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and...
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
June 01, 2023 07:57 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2023 17:10 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
May 15, 2023 16:13 ET
|
Molecular Templates, Inc.
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Molecular...
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
April 07, 2023 18:50 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (the “FDA”)...
Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
March 30, 2023 18:10 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 30, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
March 09, 2023 10:02 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...